Metrics as of 10/14/2026, 08:38 AM (Berlin time), refresh in progress.
BioCryst Pharmaceuticals Stock
BioCryst Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Charles K. Gayer
- Employees
- 435
- Market cap
- $2.1 B
- IPO
- 04/03/1994
BioCryst Pharmaceuticals, Inc. is a healthcare company in the biotechnology sector headquartered in Durham, US. The company focuses on discovering and developing novel, orally administered, small-molecule therapeutics. Its current product portfolio includes two key products. These are Peramivir injection, an…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
BioCryst Pharmaceuticals stock: price history
1D
-3.5%
1W
+1.5%
1M
-0.6%
6M
-16.5%
YTD
+3.5%
1Y
+14.6%
2Y
+8.6%
5Y
-44.2%
10Y
+99.8%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~12% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about BioCryst Pharmaceuticals
Analyst assessment of BioCryst Pharmaceuticals
PRICE TARGET LOW
US$11.00
CONSENSUS
US$19.00
MEDIAN
US$17.00
PRICE TARGET HIGH
US$29.00
0
STRONG BUY
23
BUY
6
HOLD
0
SELL
0
STRONG SELL
29
TOTAL · Buy
As of: 30/09/2026
BioCryst Pharmaceuticals stock metrics
P/E
-5.61
P/B
-4.52
EV/EBITDA
-7.61
RETURN ON EQUITY
-17.3%
NET MARGIN
35.9%
DEBT/EQUITY
-0.9
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.6%
FLOAT SHARES
214,930,907
AVG. DAILY VOLUME (30D)
5,184,111
Insider transactions (SEC)
Stonehouse Jon P
Milne Jill C.
MILANO VINCENT
McKee Amy E
Frank Steven
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.5%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about BioCryst Pharmaceuticals stock
What does BioCryst Pharmaceuticals do?
BioCryst Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Charles K. Gayer, the company employs around 435 people.
The IPO was on 04/03/1994; the stock trades on NASDAQ under the ticker BCRX.
What do analysts say about BioCryst Pharmaceuticals stock?
29 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$19.00, ranging from US$11.00 to US$29.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
When does BioCryst Pharmaceuticals report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 12% stronger than usual.
Does BioCryst Pharmaceuticals pay a dividend?
No, BioCryst Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to BioCryst Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BioCryst Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioCryst Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.